Olaison L, Belin L, Hogevik H, Alestig K
Department of Infectious Diseases, Institute of Internal Medicine, Göteborg University, Sahlgrenska University Hospital, Sweden.
Arch Intern Med. 1999 Mar 22;159(6):607-15. doi: 10.1001/archinte.159.6.607.
Long-term parenteral beta-lactam treatment is often complicated by adverse reactions that necessitate drug withdrawal.
To evaluate the incidence and mechanism of beta-lactam adverse reactions during an 8-year period in all episodes of suspected infective endocarditis in patients treated at a university-affiliated institution.
Patients with 215 consecutive episodes of beta-lactam treatment for 10 days or more were prospectively enrolled during 2 periods, January 1984 through December 1988 and January 1993 through December 1995, and compared with 51 episodes of vancomycin hydrochloride treatment for 10 days or more. Incidents of adverse reactions, such as fever, rash, or neutropenia, were registered. Neutrophil counts, eosinophil counts, and penicillin antibodies were studied. Patients with delayed adverse reactions to penicillin G sodium were rechallenged with penicillin v potassium.
Incidence of delayed adverse reactions during treatment was 33% with beta-lactams compared with 4% with vancomycin. Rates of adverse event for beta-lactams increased continuously from treatment day 15 to day 30. A 6-fold difference in capacity to induce adverse events was found with different beta-lactams. Penicillin G induced neutropenia in 14% and any adverse event in 51% of treated episodes. Mean daily doses significantly influenced the frequency of adverse events. Occurrence of hemagglutinating penicillin antibodies was significantly related to patients whose penicillin-treated episodes were complicated with adverse events. Patients with delayed adverse reactions to penicillin G were safely rechallenged with penicillin.
Incidence of delayed adverse reactions to beta-lactams increases sharply when parenteral treatment is extended beyond 2 weeks. Penicillin G is the most frequent inducer of adverse reactions among beta-lactams studied. An immunological reaction mediated by antibodies to the penicilloyl determinant may be involved in the pathogenesis, possibly enhanced by a dose-related toxic trigger mechanism. Beta-Lactam-induced neutropenia followed a uniform pattern, occurring after, on average, 21 days of treatment, and might be due to both immunologic and toxic effects of treatment. Patients with a late adverse reaction to penicillin can safely be re-treated with penicillin, although they should remain under close surveillance if treatment extends beyond 2 weeks.
长期肠外β-内酰胺治疗常因不良反应而变得复杂,这些不良反应需要停药。
评估一所大学附属医院在8年期间,所有疑似感染性心内膜炎患者接受治疗时β-内酰胺不良反应的发生率及机制。
在两个时间段前瞻性纳入连续接受β-内酰胺治疗10天或更长时间的215例患者,时间段分别为1984年1月至1988年12月以及1993年1月至1995年12月,并与51例接受盐酸万古霉素治疗10天或更长时间的患者进行比较。记录不良反应事件,如发热、皮疹或中性粒细胞减少。研究中性粒细胞计数、嗜酸性粒细胞计数及青霉素抗体。对青霉素G钠出现延迟不良反应的患者用青霉素V钾再次进行激发试验。
β-内酰胺治疗期间延迟不良反应的发生率为33%,而万古霉素为4%。β-内酰胺类药物的不良事件发生率从治疗第15天到第30天持续上升。不同β-内酰胺类药物诱发不良事件的能力存在6倍差异。青霉素G在14%的治疗病例中诱发中性粒细胞减少,在51%的治疗病例中诱发任何不良事件。日均剂量显著影响不良事件的发生频率。血凝青霉素抗体的出现与青霉素治疗病例并发不良事件的患者显著相关。对青霉素G出现延迟不良反应的患者用青霉素再次进行激发试验是安全的。
当肠外治疗时间超过2周时,β-内酰胺延迟不良反应的发生率急剧增加。在所研究的β-内酰胺类药物中,青霉素G是最常见的不良反应诱发药物。由青霉素酰决定簇抗体介导的免疫反应可能参与发病机制,可能由剂量相关的毒性触发机制增强。β-内酰胺诱发的中性粒细胞减少呈现一致模式,平均在治疗21天后发生,可能是治疗的免疫和毒性作用共同导致的。对青霉素出现晚期不良反应的患者可以安全地再次用青霉素治疗,不过如果治疗超过2周,应密切监测。